Leadership and Board of Directors
Thierry Dervieux, Ph.D. has served as our Chief Scientific Officer and Medical Laboratory Director since October 2010. Dr. Dervieux has nearly 20 years of experience with the development of drug monitoring and molecular diagnostic assays in partnership with academia and diagnostic industry. Prior to joining Exagen, Dr. Dervieux was Vice President of Research and Development with Cypress Bioscience, Inc., a pharmaceutical company with a focus on drugs to treat central nervous system disorders, where he developed our current portfolio in the rheumatology space from 2008 to October 2010. He previously served as Senior Director Research and Development with Proprius Pharmaceuticals, Inc., a specialty pharmaceutical and personalized medicine company focused in rheumatology and pain management, until its acquisition by Cypress Bioscience. Prior to that, he served as Principal Scientist and Director of Research and Development at Prometheus Laboratories. Dr. Dervieux is board certified by the American Board of Clinical Chemistry and holds certificates of qualification as medical laboratory director in the categories of cellular immunology, clinical chemistry, drug monitoring, genetic testing and diagnostic immunology. Dr. Dervieux holds Pharm.D. and Ph.D. degrees from Claude Bernard University in Lyon, France, an inter-university diploma in biostatistics from the University of Pierre et Marie Curie in Paris, France, and trained at St. Jude Children's Research Hospital in Memphis, Tennessee.
Brian McEvilly has served as our Vice President of Marketing since February 2016. Brian joined us with nearly 20 years of medical marketing experience, including his most recent role as Vice President of Marketing at WomanCare Global, a non-profit organization focused on women’s health. Mr. McEvilly gained a deep understanding of the global autoimmunity diagnostics market when he successfully lead Product Marketing for 5 years as the Director of Marketing at Inova Diagnostics, Inc. He also played an important role in the initial launch of the AVISE brand as the Director of Personalized Medicine at Cypress Bioscience from 2008-2010. The personalized medicine offering at Cypress was later acquired by Exagen, allowing Mr. McEvilly to quickly make meaningful contributions to the continued growth of this familiar franchise. Brian’s career in medical marketing began in 1998 when he excelled in various Sales and Marketing roles at Sunrise Medical, Quidel and later Gen-Probe. Mr. McEvilly holds a B.A. in Business from the University of San Diego and earned an MBA degree, graduating with honors from University of California, Irvine.
President & CEO
Fortunato Ron Rocca has served as our President and Chief Executive Officer and as a member of our board of directors since December 2011. From 2005 to October 2011,...
Dr. Thierry Dervieux
Chief Scientific Officer, Medical Director, New York
Thierry Dervieux, Ph.D. has served as our Chief Scientific Officer and Medical Laboratory Director since October 2010. Dr. Dervieux has nearly 20 years of experience...
Chief Financial Officer
Kamal Adawi has served as our Chief Financial Officer since June 2017. Kamal previously held the positions of Chief Financial Officer, Corporate Secretary and...
Arthur Weinstein, M.D.
Chief Medical Officer
Arthur Weinstein, M.D. has served as our Chief Medical Officer since October 2017 and has been a member of our board of directors since December 2013. Dr. Weinstein...
Senior Vice President Laboratory Operations
Claudia Ibarra has served as our Senior Vice President, Laboratory Operations since January 2017, after being our Vice President, Laboratory Operations from 2014. She...
Vice President of Finance
Mark Hazeltine has served as our Vice President of Finance since June 2017. Mr. Hazeltine served as Exagen’s Sr. Director of Financial Planning and Analysis...
Vice President, Information Services
Brian Littlefield has served as our Vice President, Information Services since April 2014. Prior to joining Exagen, Mr. Littlefield served as the Senior Director,...
Vice President of Marketing
Brian McEvilly has served as our Vice President of Marketing since February 2016. Brian joined us with nearly 20 years of medical marketing experience including his...
Tami Powell (York)
Vice President, Corporate Payer and Reimbursement Strategy
Tami Powell has served as our Vice President of Corporate Payer and Reimbursement Strategy since September 2017, after being our Senior Director, Corporate Payer...
Vice President, Sales & Managed Markets
John Wegener has served as our Vice President, Sales and Managed Markets since November 2013. Prior to joining Exagen, Mr. Wegener served in various capacities with...
Board of Directors
Jim Tullis founded Tullis Health Investors ("THI" or "Tullis-Dickerson & Co., Inc.") in 1986 and has a career of over 40 years in health care investing. Prior to establishing Tullis Health Investors, Jim was a Senior Vice President of E.F. Hutton & Co. (1983-1986) and a Principal at Morgan Stanley & Co. (1974-1983), where he led health care investment research and, later, healthcare investment banking. During his tenure at Morgan Stanley, he received recognition 14 times on the Institutional Investor All-Star list of Wall Street's top securities analysts and listing as a top home run hitter. He was twice named #1 Drug Analyst and was featured on the Wall Street Week television program. From 1972-1974, Jim was Vice President of Putnam Funds researching health care industry equities. Under Jim's direction, THI has managed several venture capital funds investing into the health care industry. Winning portfolio companies of those funds include Adams Respiratory and Sirion (with innovative concepts in pharmaceuticals); Synageva and BioRexis (biotechnology); Atritech and Vidacare (medical devices); PSS World Medical and Impulse Monitoring (medical services); and Intelliclaim and QuadraMed (health care information technology). Jim is a graduate of Stanford University and earned an MBA from Harvard Business School. He currently sits on the Boards of the Lord Abbett family of mutual funds, Crane Corporation (NYSE: CR), LivHOME, Inc., SupplyPro, Inc., Exagen Diagnostics, Inc., electroCore, LLC, and SafeOp Surgical, Inc.
Daniel C. Burrell has served as a member of our board of directors since October 2017. In 2002, Mr. Burrell served the Clinton Administration and also Directed West Coast Finance with John Kerry for President until its conclusion in 2004. Mr. Burrell has extensive successful leadership experience in Finance and Real Estate including the formation of Rosemont Capital, which oversaw over $400mm in assets, and subsequently serving as CEO of Rosemont Realty from 2008 until 2013, continuing on the company’s Board for several years thereafter. In 2014, Mr. Burrell served as Founder, Executive Chairman, and CEO of The Burrell College of Osteopathic Medicine (BCOM), the nation’s first independently accredited, privately financed, university-affiliated college of medicine in the United States. Located in New Mexico, BCOM’s mission is to address chronic doctor shortages in rural and underserved areas and a second medical school is underway in Idaho. As an active leader and philanthropist, Mr. Burrell is Chairman and CEO of The Burrell Group, Co- Chairman and CEO of CryptoWatt, Managing Director and Principal of BG Life Sciences and Technology Fund, and Founder and Chairman of the New Mexico Leadership Institute and The Burrell Centers for Health Policy and Research. Mr. Burrell received a Bachelor of Arts and Sciences degree from Georgetown University, a J.D. from Yale University, and a General Course Degree from the London School of Economics. He lives in Aspen, Colorado.